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Abstract: 
Objectives: To examine any association of necrotizing enterocolitis (NEC) and intestinal 
perforation (IP) in very low birth weight neonates with indomethacin treatment, cumulative dose 
or maximum plasma concentrations. Methods: This is a retrospective 9-year cohort study of very 
low birth weight infants ( < 1500 grams) admitted to our neonatal intensive care unit. The 
incidence of NEC and IP in infants who received indomethacin for a PDA (N = 228) were 
compared to control infants who did not have PDA and received no indomethacin (S = 628). 
Factors which were statisticaily significant in a univariate analysis were then included in a 
logistic regression model to determine their significance. Results: NEC occurred in 14 (6.1 %) 
indomethacin-treated infants compared to 47 (7.5%) control infants. When the incidence of NEC 
or IP was restricted to events occurring within 14 days of indomethacin, infants (1.7%) had NEC. 
JP occurred in 14 (6.1 %) indomethacin-treated infants, but 10 had concurrent steroid therapy. IP 
also occurred in 4 (0.6%) controls. Multivariate logistical regression revealed a lower risk of 
NEC with indomethacin. The risk for NEC and IP is not increased with higher INDO doses or 
INDO concentrations. Conclusions: Indomethacin treatment for PDA does not increase NEC 
risk, and may decrease the risk. Indomethacin treatment is associated with an increased risk of 
IP, especially when combined with systemic glucocorticoids. 




When indomethacin (INDO) became a widely accepted agent for patent ductus arteriosus (PDA) 
closure in premature infants, concerns of gastrointestinal toxicity were prominent in monitoring 
outcomes [1-3] Particularly concerning was the risk of causing necrotizing enterocolitis (NEC), 
since this illness is associated considerable morbidity and mortality [4,5]. Several studies 
suggested that a causal association between indomethacin therapy for PDA with NEC or 
intestinal perforation (IP) does exist [2,3,5,6]. This conclusion is confounded by data indicating 
that PDA is itself a cause of NEC [7]. More recent smdies did not demonstrate a causal 
relationship between indomethacin and NEC or IP [8-11). When combined with postnatal 
steroids, INDO was associated with NEC or IP [10-13]. This study is a retrospective cohort 
analysis, designed to further clarify whether INDO therapy is associated with an increased risk 
for NEC or IP. It provides a unique examination of the relationship of INDO dose and INDO 
concentration to gastrointestinal toxicity. We also consider the alternative argument that INDO 
may be protective of NEC. 
2. Materials and methods 
2.1. Study design and population 
This study was approved by the IRB and exempted from individual informed consent. The data 
collection and analysis were all done retrospectively and no interventions were made for the 
purpose of the study. All very low birth weight infants ( ≤ 1500 grams) admitted to the level III 
NICU at Women's Hospital between January 1997 and December 2005 were included in this 
retrospective analysis. Data was obtained from an ongoing access database maintained on a 
continuous basis and reported annually to the Vermont Oxford Network. 
Infants who received indomethacin for a PDA (N =228) were compared to control infants who 
received no indomethacin and did not have a clinically or hemodynamically detectable PDA (N= 
628). Patients were evaluated for PDA using echocardiography when clinical signs (e.g. murmur, 
wide pulse pressures, hypotension, etc.) of PDA were detected, or oxygen or ventilator demands 
raised suspicion of a silent PDA. 
INDO was only used to treat echocardiography confirmed PDA. Patients who received 
indomethacin were dosed according to combined pharmacokinetic-pharmacodynamic modeling 
with ultimate dosing individualized to patient response [14,15]. Initial INDO doses were 0.25 to 
0.3 mg/kg, and INDO plasma concentrations were measured 2 and 8 hours after each INDO 
dose. INDO doses were then individually adjusted based on clinical response or 
echocardiography proven PDA closure if symptoms of PDA resolved. Individual maintenance 
INDO doses ranged from 0.1 to 0.5 mg/kg every 8 -12 hours based on whether the effective 
INDO concentration is to be maintained or higher INDO concentrations were needed because of 
inadequate response. 
In addition to indomethacin dose, data were also collected on other potential covariates 
including: gestational age, birth weight, 5-minute Apgar score, plurality, maternal hypertension 
during pregnancy, presence of chorioamnionitis in mother at the time of birth, administration of 
surfactant as an indicator of early RDS, administration of postnatal steroids, presence of early 
infection at ≤ 3 days of life, presence of late infection at ≥ 7 days of life, pressor support as an 
indication of blood pressure instability, umbilical catheter placement, days with umbilical 
catheter, need for mechanical ventilation, and days on mechanical ventilation. 
NEC and IP can be difficult to separate clinically [10, 16], which could confound results. 
Diagnosis of NEC or IP involved a shared evaluation by the attending neonatologist and 
consulting pediatric surgeon. In IP cases, the diagnosis was confirmed by exploratory 
laparoscopy or therapeutic surgery. This was also the case in approximately half the NEC cases, 
with the remainder diagnosed clinically and radiographically. Clinically, patients presented with 
recognized signs and symptoms such as feeding intolerance, abdominal distention, lethargy, 
ileus, and abdominal x-ray showing pneumatosis intestinalis or free air [ 4, 16, 17]. All neonates 
with NEC developed concurrent signs of suspected or confirmed sepsis, requiring antibiotic 
therapy. 
Feeding strategies varied among patients with breast milk being preferred, and int1mt formula 
being used when breast milk was not available or contained contraindicated medications. 
Formula selection was made on an individual basis. Oral feeds were not initiated while the 
ductus was open or INDO doses were being administered, and were withheld for 48 hours after 
the last INDO dose. Feeding was started with 3 to 5 days at 10 to 20 mL/kg/day ("trophic 
feeds"), and then volume was increased by 10 to 20% of total feeds per day based clinical 
perceptions of how well each feeding increase was tolerated. 
2.2. Statistical analysis 
Based on an assumed NEC rate of7% in the control group, the sample size was sufficiently large 
for a power of 0.9, with an alpha of 0.05, to detect an increase to 8% in the 1\EC rate for 
indomethacin-treated PDA patients. 
Variables (Table 1) were evaluated with multiple logistic regression. The base model included 
gestational age, 5 minute APGAR, and birth weight. The additional variables were screened for 
testing in the starting multivariate model based on their univariate prognostic value. Variables 
with univariate Wald chi-square p-values less than 0.25 were included in the final model. 
Ultimately, backwards elimination was used to derive a final model. Variables with p-values less 
than 0.05 were considered statistically significant. The final model was evaluated with the chi-
square deviance test and Hosmer and Lemeshow goodness of fit test. All analyses were 
performed with SAS software (Cary, NC). Predictors of NEC were evaluated with multiple 
logistic regression. The base model included gestational age, 5 minute APGAR, and birth 
weight: these three variables have known clinical importance for predicting NEC. Twenty 
additional variables were screened for testing in the starting multivariate mode 1 based on their 
univariate prognostic value. Of these, ten were considered promising predictors (univariate Wald 
chi-square; p < 0.25). Finally, backwards elimination was used to derive a final model from these 
13 variables. Variables with p-values of less than 0.05 were considered statistically significant. 
The final model fit was evaluated with the chi-square deviance test and Hosmer and Lemeshow 
goodness of fit test. Additional variables retained in the final models were total INDO, late 
infection, ventilation duration, ventilation insult, and OAC/UVC insult. All analyses were 
performed with SAS (Cary, NC) software. 
Table 1. Demographic comparison of neonates with PDA + INDO treatment and controls 
 Indo (228)  No Indo (628) 
Gestational Age (wks) 26.7*  28.7 
Birthweight (g)  860*  1060 
5-minute APGAR (median)  7  7 
Plurality (median)  1 1 
Chorioamnionitis (%)  4.8  4 
Maternal HTN (%)  23.7  29 
Early infection (%)  0.9*  0.5 
Late infection (%)  31.1*  11.6 
Pressor support (%)  45.6*  16.4 
Pressor support (days)  l.6*  0.5 
Surfactant (~lo)  74.6*  42.5 
UVC/UAC placed(%)  96.5*  69.6 
UAC/UVC (days)  7.9*  4 
Ventilator(%)  91.2*  55.1 
Ventilator (days)  16.2*  6.1 
*p < 0.01. 
3. Results 
Demographic data and presence of risk factors for neonates to develop KEC or IP are listed in 
Table 1. Indomethacin-treated neonates had significar1tly lower gestational age and birth weight, 
lower Apgar scores, and higher incidence of other risk factors associated with NEC or IP. As was 
observed in a similar examination of risk factors for ~EC and its association with indomethacin 
[11 ], we identified gestational age, birthweight, mechanical ventilation, exposure to surfactant, 
exposure to postnatal glucocorticoids, and umbilical artery catheters important statistical factors 
to include in our multivariate analysis. We also found statistically important differences in the 
incidence of early and late-onset culture-confirmed infections, the need for vasopressor support, 
the need for intubation and the length of time on mechanical ventilation, and duration of 
umbilical artery or umbilical vein catheter placement (Table 1) These all favored the control 
group as being at less risk of NEC. 
When infants treated with indomethacin were followed over the entire course of their NICU stay, 
there was a similar incidence of NEC between infants treated with indomethacin for PDA and 
infants with no PDA and no indomethacin therapy (6.1% vs. 7.5%, p > 0.10). There was a 
significantly increased risk of IP associated with indomethacin therapy for PDA (6.14% vs. 
0.64%, p < 0.01). The postnatal age of neonates developing NEC was a median of29 days (range 
6 to 68 days), and for neonates developing IP was a median Of 9 days (range 2 to 75 days). The 
postnatal ages did not differ for the INDO and control groups developing NEC or IP. 
As with the study by Attridge et al. [I 0], we required that NEC or IP occur within 2 weeks of 
exposure to INDO to reasonably link INDO as a cause. Analyzing data with this restriction, there 
is a significant decrease in the incidence of NEC between infants treated with INDO for PDA 
and infants with no PDA and no indomethacin therapy (1.7% vs. 7.5%, p < 0.01). The 
significantly increased risk of IP remains in the PDA/indomethacin group compared to controls 
(5.2% vs. 0.6%, p < 0.001) The IP rate however is largely impacted by the cases where postnatal 
glucocorticoids were administered (Fig. 1). Only 4 (1.7%) cases occurred in the INDO group, 
and one case (0.2%) in the control group, where glucocorticoids were not potentially involved. 
On a separate note, because of their significance in the Attridge study [10] we also recorded the 
early use of hypotension treatment. Of the 14 IP cases, 9 neonates were treated with early blood 
pressure medications, i.e. dopamine, dobutamine, or both, at various doses. 
Multivariate logistical regression revealed similar favorable results concerning the aggressive 
treatment of PDA with indomethacin and causal relationship with NEC. Indomethacin treatment 
for PDA was associated with a decreased risk of KEC, controlling for gestational age, 5 minute 
APGAR, birth weight, late infection, ventilation duration, ventilation insult, and UAC/UVC 
insult (p-value = 0.0265). A Hosmer and Lemeshow goodness of fit test finds no evidence to 
reject the hypothesis that indomethacin treatment for PDA is not a statistically significant risk 
factor for NEC (p-value = 0.37). 
 
Fig. 1. Summary of rates ofNEC ancl!P in neonates treated with indomethacin (INDO) and 
controls. 
 
Fig. 2. Relationship of cumulative INDO dose in mg/Kg to percent of patients with NEC or IP 
for all events occurring any time after INDO doses. INDO close categories were selected to 
allow sufficient patient numbers in each group: 0, 62R patients; 0.1-0.6 mg/Kg, 28 patients; 
0.61--0.9 mg/Kg, 54 patients: 0.91-1.2 mg/Kg, 66 patients; 1.21-l.S mg/Kg, 36 patients; and ≥ 
1.51 mg/Kg, 44 patients. x-axis = cumulative INDO dose (mg/Kg); y-axis =%of patients with 
event any time post-INDO. 
The total treatment dose for each indomethacin-treated neonate was analyzed to examine any 
relationship between this variable and development of NEC or IP. Indomethacin total doses 
ranged from 0.25 to 3.55 mg/kg, and indomethacin maximum concentrations ranged from 0.67 to 
5. 77 mg/L (1.87 to 16.10 μmol/L). The mean (SD) for indomethacin doses for the three groups 
were: 1.06 (0.56) mg/Kg for INDO-controls; 1.28 (0.85) mg/Kg for NEC; and 1.06 (0.35) mg/Kg 
for IP. None of these are statistically different from the others. No trend was found toward 
increased NEC or IP risk with higher doses of indomethacin, whether all NEC and IP events 
were included (Fig. 2), or only those with an event within 14 days of completing indomethacin 
therapy (Fig. 3). Maximum indomethacin plasma concentration, also appear to lack any 
statistical relationship to NEC or IP. Indomethacin concentrations (mean, SD) were: 2.44 (1.05) 
mg/L (6.81, SD 2.93 for INDO controls; 2.32 (0.46) mg/L (6.48, SD 1.29 ,μmol/L) for NEC; and 
2.47 (1.00) mg~l. (6.89, SD 2.79 μmol/L) for IP. None of these groups were statistically different 
from each other. Furthermore, the rates of NEC or IP were not different at different 
indomethacin plasma concentration categories (Figs 4 and 5). The lack of a clear dose-response 
and concentration-response relationship, makes it more likely that indomethacin does not cause 
NEC. For IP, systemic glucocorticoids appear to be a major risk, accounting for 13 of 18 IP cases 
(Fig. 6), and indomethacin may exaggerate this risk as an additive or synergistic toxicity. The 
risk of IP was 7.1 times greater for combined indomethacin+ systemic steroids (25%) than for 
indomethacin alone (3.5%), and 11.4 times the risk for systemic steroids alone (2.2%). IP was 
rare (0.2%) in the absence of systemic steroids or indomethacin. 
4. Discussion 
The etiology of NEC is unknown, but multiple risk factors have been implicated in its 
pathogenesis. The risk of NEC is greatly increased by early birth and very low birth weight, 
occurring in about 7% of neonates below 1500g birth weight [4]. Near term fetal lambs were 
shown to have increased risk of adverse gastrointestinal effects from either the presence of a 
PDA or from indomethacin exposure in lambs with closed ductus arteriosus [18]. This was due 
to reduced blood flow to the terminal ileum, placing this area at higher risk for intestinal 
ischemia. PDA has also been shown to be a risk factor for XEC in premature infants [7]. Cassady 
et al. established that surgical closure of the PDA on day l of life reduces the risk of KEC in 
neonate with birth weight below 1000 g from 30% in untreated neonates, to 8% with PDA 
ligation [7] Infants in our study with a PDA treated with indomethacin therapy and the control 
patients, showed a similar rate of NEC to the prophylactic ligation group in the study by Cassady 
and colleagues [7]. 
 
Fig. 3. Relationship of cumulative INDO dose in mg/Kg to percent of patients with NEC or IP 
for events that occurred between starting INDO and 14 days after completing INDO. rNDO dose 
categories were selected to allow sufficient patient numbers in each group: 0, 62R patients; 0.1-
0.6 mg/Kg, 28 patients; 0.61-0.9 mg/Kg, 54 patients; 0.91-1.2 mg/Kg, 66 patients; 1.21-1.5 
mg/Kg, 36 patients; and ≥ 1.51 mg/Kg, 44 patients. x-axis = cumulative INDO dose (mg/Kg); y-
axis =%of patients with event :s:; 14 days post-INDO. 
Some studies link the treatment of POA with indomethacin to an increased risk of 1\'EC. Nagaraj 
et al. [3] reported KEC and focal perforation problems in 21 (26%) of 82 infants treated with 
indomethacin for POA. The high rate of gastrointestinal complications (13 NEC, 8 local 
perforation) may partly be explained by the unusual indomethacin regimen of 0.2 mg/kg every 8 
hours given orally or rectally. A comparison group of 30 patients managed conservatively or 
with surgical ligation, had only 3 NEC episodes for a gastrointestinal complication rate of 1 0%. 
Given the known local gastrointestinal toxicity of oral NSAIDs, few centers are using oral 
indomethacin as a treatment for PDA closure. Grosfeld and colleagues [5] examined 252 
premature infants with symptomatic POA given intravenous indomethacin in an attempt to close 
the ductus arteriosus. Surgical ligation was performed in 11% of patients, and 35% of infants 
developed NEC after INDO therapy. Factors associated with the onset of NEC included 
gestational age less the 28 weeks, birth weight less than 1 kg, and prolonged ventilator support. 
The patients with PDA who received indomethacin therapy were compared with a control group 
of 764 infants with similar sex, birth weights, and gestational ages without POA or indomethacin 
therapy. NEC occurred in 13.7% of control patients vs. 35% in indomethacin-treated group (JJ < 
0.02). Fujii et al. [6] compared treatment with INDO in the first 48 hours of life to avoid the 
necessity ofPDA ligation versus standard symptomatic treatment with indomethacin after48 
hours of life in 65 extremely premature infants ( < 27 weeks). The study concluded that early use 
reduced the need for PDA ligation (5% vs. 35%, p = 0.033) but increased the risk Of NEC (20% 
vs. 0%, p = 0.011). Of the 30 infants<27 weeks gestational age receiving early therapy, only 1 
patient required surgical ligation but 6 developed NEC. Three of the KEC patients also received 
dexamethasone. Of the 32 infants < 27 weeks gestational age receiving standard therapy, 6 
underwent surgical ligation, but none developed NEC. These data suggest a correlation between 
the early use of indomethacin and the development of NEC in extremely premature infants. 
Other studies provide evidence against indomethacin causing NEC at higher rates than PDA 
surgical closure or a control group without PDA [8,9, 11, 19]. These are generally better 
designed and larger trials than those associating NEC with indomethacin therapy. Some trials 
found that exposure to indomethacin on days l-3 of life was associated with IP, but later 
exposure was not associated with increased IP risk [10]. Our use of indomethacin varied as 
treatment was started only after PDA became symptomatic, often beyond the third day of life. 
This study also noted the importance of concurrent systemic glucocorticoids and early use of 
vasopressors. We also had several patients treated with dopamine or dobutamine, but since their 
use paralleled indomethacin use and presence of PDA, we could not distinguish their possible 
role in IP. 
The use of both indomethacin and systemic glucocorticoids has been associated with increased 
risk for NEC [11] and IP [10,20], even when indomethacin alone did not cause a statistically 
significant increase. Paquette et al. [12] also failed to show an association between indomethacin 
therapy and IP, but when the combination of early indomethacin and dexamethasone was 
examined, patients were 9.6 times more likely to develop IP. Watterberg et al. [ 13] were forced 
to discontinue their trial of early hydrocortisone to prevent bronchopulmonary dysplasia, because 
of the high rate of IP. In the prophylactic indomethacin plus hydrocortisone group, IP occurred in 
12% of patients, compared to 2% with hydrocortisone alone and 1% with indomethacin alone. 
Stark et al. [20] reported IP rates of 19% with combined dexamethasone and indomethacin and 
5% of indomethacin alone. This was significantly higher than placebo, where no IP cases 
occurred. The combination of indomethacin and systemic steroids seems to be particularly toxic 
to the gastrointestinal mucosa. This seems to be the case in our study also, where 8 of 12 IP cases 
were exposed to both indomethacin and systemic steroids. 
 
Fig. 4. Relationship of highest INDO plasma concentration (mg/L) to percent of patients with 
NEC or IP for all events. INDO concentration categories were selected to allow sufficient patient 
numbers in each group: 0 mg/L, 628 patients; 0.1-1.5 mg/L (0.28-4. 19 μmol/L), 26 patients; 
LSl-3.0 mg/L (4.22-8.38 μmol/L), 112 patients; and 3.01-5.8 mg/L (8.41-16.21 μmol/L), 71 
patients. x-axis =highest INDO concentration (mg/L); y-axis =% of patients with event any time 
post-INDO. 
 
Fig. 5. Risk for IP among neonates exposed to indomethacin (INDO) and systemic steroids alone 
or in combination. 
Our results strengthen the argument that indomethacin docs nm cause NEC, but rather is 
frequently used in neonates at high risk for ~EC. While the reason for an apparent reduction in 
NEC rate with INDO treatment is unclear, the process of inflammation is known to be important 
in the pathogenesis of NEC and perhaps it is the anti-inflammatory effects of INDO that account 
for any benefit [17]. Also, stabilizing or closing the PDA may help reduce the risk of NEC [8]. 
These reasons are speculative and needs confirmation in future studies. On the other hand, IP 
does appear to be more likely to occur when indomethacin is used, particularly in combination 
with systemic glucocorticoids. There are several theories about the reason for the high IP risk 
when indomethacin is combined with steroids, including: thinning of the muscularis and 
thickening of the adjacent mucosa; and inhibition of local prostacycline and nitric oxide 
production, resulting in diminished perfusion of the watershed areas of the ileum [16]. 
The need to close PDA in very-low-birth-weight infants is supported by most practitioners, based 
on clinical and research observations [21-23]. The options to date have been pharmacologic with 
indomethacin, or more recently ibuprofen, and surgical ligation. Recent studies have created 
profound concerns about the adverse impact of surgical closure of PDA on neurosensory 
function, chronic lung disease and mortality [24-26]. It is likely that pharmacologic closure of 
PDA will be increasingly important, and higher doses may be used to achieve PDA closure in 
over 90% of patients [16, 27]. 
The relationship of indomethacin doses and concentrations in neonates to the development of 
NEC and IP, two gastrointestinal complications associated with indomethacin treatment has not 
previously been examined. This is in part because standard indomethacin doses are traditionally 
used precluding the opportunity to explore the impact of a wide range of doses. A previous paper 
by Sperandio et al. [27] explored a wide range of indomethacin doses to achieve a PDA closure 
rate of 98%. These authors report only 1 case of IP in 129 neonates treated with indomethacin, 
although this was one of the 61 infants who received> 1.5 mg/kg total indomethacin dose. The 
rate of NEC was 6% in neonates receiving ~ .5 mg/kg, and only 3% in those receiving > .5 
mg/kg, suggesting an absence of a relationship with a total indomethacin dose. Our study failed 
to identify a relationship with NEC or IP and increasing indomethacin doses or concentrations 
(Figs 2-5). 
There are several limitations to our study. These limitations are similar to other retrospective 
cohort studies related to indomethacin toxicity. The cohorts in this study are different in several 
demographic features. These include the indomethacin group being significantly less mature, 
smaller, requiring more blood pressure support and more respiratory support. The study actually 
reflects the impact of PDA and indomethacin versus a control group with neither of these 
problems. However, considering the other increased risk factors for NEC, it is impressive that 
the indomethacin-treated patients actually had less NEC. Another potential issue is the impact of 
other management changes that may have occurred during this 9-year study. However, we did 
not see a directional change in the rate of NEC or IP associated with different years. 
5. Summary 
Indomethacin treatment for PDA is not associated with NEC and may actually be protective of 
NEC caused by hemodynamically significant PDA. IP however, is associated with indomethacin 
treatment, and is a particularly high risk when indomethacin and systemic corticosteroids are 
combined. This is the first study to examine the relationship of indomethacin dose and 
concentrations to NEC or IP using such a wide range of doses and concentrations. Since neither 
NEC nor IP were associated with increasing doses of indomethacin, higher dosing strategies with 
indomethacin need not be avoided purely on the basis of concerns for gastrointestinal toxicity. 
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